Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
473.29
+8.36 (1.80%)
NASDAQ · Last Trade: Dec 3rd, 6:39 PM EST
Detailed Quote
Previous Close
464.93
Open
466.48
Bid
459.65
Ask
477.80
Day's Range
460.41 - 479.79
52 Week Range
205.87 - 495.55
Volume
1,092,899
Market Cap
56.25B
PE Ratio (TTM)
631.05
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
992,991
Chart
About Alnylam Pharmaceuticals, Inc. - Common Stock (ALNY)
Alnylam Pharmaceuticals is a biopharmaceutical company focused on advancing innovative therapies using RNA interference (RNAi) technology to treat a range of genetic diseases. The company is dedicated to developing medicines that can selectively silence disease-causing genes, thereby addressing the underlying causes of conditions such as hereditary transthyretin-mediated amyloidosis and other rare disorders. With a strong commitment to research and development, Alnylam aims to deliver transformative treatments that improve patient outcomes and enhance quality of life for those affected by severe or life-threatening diseases. Read More
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced changes to its Board of Directors, including the departure of two directors and the appointment of a new independent director. Mike Bonney and Carolyn Bertozzi, Ph.D., who have served in key roles on Alnylam’s Board, stepped down effective December 2, 2025.
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults. Data from cardiovascular magnetic resonance (CMR) and echocardiographic imaging as well as renal function analyses were presented at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, Louisiana.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:
Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion.
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights.
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome Powell th
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open.
The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the potential catalysts driving attention.
Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by the company's recent strategic guidance, which forecasts over $5 billion in potential annual peak sales from its robust pipeline of
